A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment

Status unconfirmed · Phase 2

Conditions studied: Metastatic Pancreatic Cancer

In brief

TL-118 is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Tl-118 comprises of four well-known active components. The therapy is administrated at a unique dosing regimen that was found to be effective and advantageous in terms of safety. The product is formulated as an oral suspension, conveniently administrated by the patients at home and not requiring medical staff assistance. This Phase II clinical trial aims to evaluate the efficacy, safety and tolerability of TL-118 in Gemcitabine treated Pancreatic Cancer patients

Key facts

Study ID

NCT01509911

Run by

Tiltan Pharma Ltd.

People needed

99

Starts

2012-01-01

Expected to finish

2017-01-01

Last updated by the study team

2016-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age at least 18 years at enrollment.
• Metastatic Pancreatic Cancer
• The patient has histologically or cytologically confirmed pancreatic adenocarcinoma.
• Patient has measurable disease by (RECIST).
• Patient is starting standard of care Gemcitabine treatment
• ECOG performance status ≤ 1
• Adequate renal function
• Adequate hepatic function
• Adequate bone marrow reserve
• Resolution of prior therapy acute adverse events.
• Patient is capable of swallowing.
• Patient's Informed Consent. -

You may not qualify if…

• Hypersensitivity to one or more of the TL-118 active components
• Known Glucose-6-phosphate-dehydrogenase deficiency (G6PD).
• CNS or Brain metastases
• Prior systemic therapy for pancreas cancer
• Subjects who received any investigational medication, prior local therapy for pancreas cancer , or any significant change in treatment within 1 month prior to screening
• Concurrent use of any other investigational product
• Subjects with a clinically significant or unstable medical condition that would preclude safe and complete study participation
• Use of supplements or complementary medicines/botanicals, except for conventional multivitamin supplements, calcium, selenium and soy supplements.
• Patient has known historical or active infection with HIV, hepatitis B, or hepatitis C
• Circumstances likely to interfere with absorption of orally administrated drugs.
• History of noncompliance to medical regimens or coexisting -

Where it is running

• Emory Clinic — Atlanta, Georgia, United States
• White Plains Hospital — White Plains, New York, United States
• Assaf Harofe Medical Center — Ẕerifin, Zerifin, Israel
• HaEmek Medical Center — Afula, Israel
• Soroka Medical Center — Beersheba, Israel
• Hillel Yaffe Medical Center — Hadera, Israel
• Rambam Medical Center — Haifa, Israel
• Hadassah Medical Center — Jerusalem, Israel
• Sheba Medical Center — Ramat Gan, Israel
• Sourasky Medical Center — Tel Aviv, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.